

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

[url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences:Wells Fargo 21st Annual Heal

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healthcare Conference in Boston, MA Wednesday, September 9, 2026 at 8:00 a.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York City Wednesday, September 16, 2026, at 10:45 a.m. Eastern Time Bank of America Global Healthcare Conference in London, UK Tuesday, September 22, 2026, at 6:45 a.

Bruker Energy and Supercon Technologies (BEST), a segment of [url="]Bruker Corporation[/url] (Nasdaq: BRKR), and Luvata Materials and Solutions, a Business Unit of

HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-generation magnetic confinement fusion power demonstration plant projects worldwide.The BEST-LUVATA collaboration aims to further strengthen and e.

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Deutsche Bank AG acquired a new stake in Bruker Corporation (NASDAQ: BRKR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,914 shares of the medical research company's stock, valued at approximately $1,439,000. Other large investors have also

Bank of New York Mellon Corp acquired a new stake in Bruker Corporation (NASDAQ: BRKR) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 745,079 shares of the medical research company's stock, valued at approximately $44,839,000. Bank of New York Mellon Corp